Novartis sets sights on high-value medicines and US market
Swiss pharma giant Novartis has unveiled an updated strategy focused on high-value medicines and boosting its position in the US market. It also confirmed that its generics unit Sandoz would be spun off by the end of 2023.
This content was published on
3 minutes
Keystone-SDA/jdp
Português
pt
Novartis se concentra em medicamentos de alto valor e mercado americano
During the annual investor day meeting in Basel, Novartis outlined its plan to become what it calls a “pure-play” innovative medicines company after the Sandoz spin-off operation is complete. After a strategic review, Novartis announced in August that it plans to spin off the generics and biosimilars division, which reaped $9.8 billion (CHF9.4 billion) in worldwide sales last year, but has seen revenue decline in its key market in the US.
Novartis will focus on five disease areas, key technology platforms like cell and gene therapies, and eight brands that it believes have multi-billion-dollar sales potential. Among these are Zolgensma, a $2.1 million gene therapy for spinal muscular atrophy, and Scemblix (asciminib), which was recently approved by US regulators for chronic myeloid leukemia.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
The focus on key brands is also intended to help the company boost sales in the US market. In a statement, the company said that it is taking a ‘US-first’ mindset with the aim to “improve competitive positioning” and “become a top-five player in the US by 2027”. Novartis has lagged behind US-based companies such as Pfizer and Johnson & Johnson, ranking tenth in terms of sales in the US market. It also seeks to improve its position in the Chinese market from fifth to third.
This focus on specific high-value brands and the US market, said CEO Vas Narasimhan, is part of an aim to “increase value per new molecular entity” from the company’s pipeline. By 2027, the company expects to achieve average annual sales growth of 4%.
Since Narasimhan took over the CEO post in 2018, Novartis has been shedding parts of its business. It sold its consumer healthcare unit to GSK and spun off its eyecare division Alcon into a separate entity in 2019.
In April Novartis announced a major restructuring to focus on “innovative medicines” – combining its pharmaceutical and oncology divisions. This led the company to shed 7% of its workforce globally. In Switzerland, it said it would cut 10% of its workforce, which means 1,400 jobs will disappear, many of which are in management positions.
In August, the company said it planned to sell off the Sandoz generics unit, which is the last name of the pre-Novartis era, which goes back more than 100 years to the chemical dye industry in Basel. On Thursday, the company confirmed that Sandoz will be spun off by the end of 2023.
More
More
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
What can be done to protect biodiversity in your country?
Swiss voters are set to decide on a people’s initiative calling for better protection of ecosystems in the country. Have your say on the September 22 vote.
Switzerland to host Ukraine mine action conference in October
This content was published on
Together with Ukraine, Switzerland is organising the Ukraine Mine Action Conference (UMAC2024) in Lausanne on October 17 and 18.
Switzerland revises pension expenditure downwards by billions
This content was published on
The Swiss government has corrected downwards the projected expenditure on old-age and survivor insurance in 2033 by CHF2.5 billion ($2.66 billion).
Excess mortality rate post-Covid could persist until 2033
This content was published on
According to a report by reinsurer Swiss Re, many countries are still experiencing excess mortality following the Covid-19 pandemic.
Swiss Army ends clean-up operation in storm-hit Maggia Valley
This content was published on
The Swiss Armed Forces completed 76 flight hours during the clean-up operation following the storm in the Maggia Valley in Ticino at the end of June.
Swiss cruise ship stranded on Danube River after heavy rains
This content was published on
Passengers on a Swiss river-cruise ship stranded on the Danube following heavy rainfall are still unable to disembark in Vienna due to flooding.
Golden eagles get better at flying over time, say Swiss researchers
This content was published on
Golden eagles perfect their flight as they age and learn to make better use of air currents, says a new study co-produced by Swiss researchers.
This content was published on
Public libraries in Switzerland recorded 46.3 million admissions last year, 7.4 million more than in 2022, says the Federal Statistical Office.
Swiss conservative party seeks referendum against Eurovision contest
This content was published on
The Swiss Federal Democratic Union is launching a referendum to prevent the Eurovision Song Contest from taking place in Basel next year.
Switzerland nabs 15 medals at WorldSkills championship
This content was published on
Swiss professionals have won 15 medals at the WorldSkills Championships in Lyon, France for the best finish by a European nation.
Can Novartis’s sustainability-linked bond make good on its promises?
This content was published on
Novartis’s sustainability-linked bond was a world first for the pharmaceutical industry. But will it improve access to medicine?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.